NASDAQ:LYEL

Lyell Immunopharma - LYEL Stock Forecast, Price & News

$3.85

-0.08 (-2.04%)

(As of 12/7/2022 12:00 AM ET)

Add

Compare

Today's Range: $3.83
▼
$4.01
50-Day Range: $3.85
▼
$8.09
52-Week Range: $3.57
▼
$10.33

Volume: 723,336 shs
Average Volume: 1.04 million shs
Market Capitalization: $959.91 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $8.33

Lyell Immunopharma MarketRank™ Forecast

Analyst Rating: Hold
2.33 Rating Score
Upside/Downside: 116.5% Upside
$8.33 Price Target
Short Interest: Bearish
23.37% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: Selling Shares
$71,040 Sold Last Quarter
Proj. Earnings Growth: Decreasing
From ($1.00) to ($1.22) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.96 out of 5 stars

Medical Sector

771st out of 1,027 stocks

Pharmaceutical Preparations Industry

377th out of 503 stocks

3.2

Analyst's Opinion

Consensus Rating
Lyell Immunopharma has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $8.33, Lyell Immunopharma has a forecasted upside of 116.5% from its current price of $3.85.
Amount of Analyst Coverage
Lyell Immunopharma has only been the subject of 3 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
23.37% of the float of Lyell Immunopharma has been sold short.
Short Interest Ratio / Days to Cover
Lyell Immunopharma has a short interest ratio ("days to cover") of 16.5, which indicates bearish sentiment.
Change versus previous month
Short interest in Lyell Immunopharma has recently decreased by 2.53%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Lyell Immunopharma does not currently pay a dividend.
Dividend Growth
Lyell Immunopharma does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for LYEL.

2.6

News and Social Media Coverage

News Sentiment
Lyell Immunopharma has a news sentiment score of 1.60. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.46 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Lyell Immunopharma this week, compared to 1 article on an average week.
Search Interest
Only 4 people have searched for LYEL on MarketBeat in the last 30 days. This is a decrease of -20% compared to the previous 30 days.
MarketBeat Follows
Only 1 people have added Lyell Immunopharma to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Lyell Immunopharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $71,040.00 in company stock.
Percentage Held by Insiders
25.80% of the stock of Lyell Immunopharma is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
40.25% of the stock of Lyell Immunopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Lyell Immunopharma are expected to decrease in the coming year, from ($1.00) to ($1.22) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Lyell Immunopharma is -4.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Lyell Immunopharma is -4.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Lyell Immunopharma has a P/B Ratio of 0.99. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Lyell Immunopharma (NASDAQ:LYEL) Stock

Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness. Its pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer and triple negative breast cancers; LYL845, that targets multiple solid tumors; and NY-ESO-1 for synovial sarcoma and other solid tumor indications. The company entered into research and development collaboration and license agreement with GlaxoSmithKline for NY-ESO-1 program. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

Receive LYEL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lyell Immunopharma and its competitors with MarketBeat's FREE daily newsletter.

LYEL Stock News Headlines

December 1, 2022 | finance.yahoo.com

Lyell Immunopharma to Participate in BofA Securities Biotech Conference

November 12, 2022 | finance.yahoo.com

Earnings Beat: Lyell Immunopharma, Inc. (NASDAQ:LYEL) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

November 12, 2022 | benzinga.com

Goldman Sachs Downgrades Lyell Immunopharma to Neutral

November 10, 2022 | finance.yahoo.com

Lyell Immunopharma Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues Lag

November 10, 2022 | finance.yahoo.com

Lyell Immunopharma to Participate in Barclays Virtual Fireside Chat Series

November 8, 2022 | finance.yahoo.com

Lyell Immunopharma (LYEL) Reports Q3 Loss, Lags Revenue Estimates

November 8, 2022 | finance.yahoo.com

Lyell Immunopharma Reports Recent Business Highlights and Third Quarter Financial Results

November 7, 2022 | finance.yahoo.com

Lyell Immunopharma Presents New Data at SITC Highlighting its Growing Pipeline of T – Cell Reprogramming Technologies and Product Candidates Targeting Solid Tumors

November 4, 2022 | finance.yahoo.com

Lyell Immunopharma (LYEL) Expected to Beat Earnings Estimates: Should You Buy?

November 2, 2022 | finance.yahoo.com

Lyell Immunopharma to Participate in Credit Suisse Healthcare Conference

October 17, 2022 | finance.yahoo.com

Institutional owners may take dramatic actions as Lyell Immunopharma, Inc.'s (NASDAQ:LYEL) recent 7.5% drop adds to one-year losses

October 6, 2022 | morningstar.com

Lyell Immunopharma Shares Climb 11% After FDA Approves IND For LYL845

October 6, 2022 | markets.businessinsider.com

FDA Approves Lyell Immunopharma's IND For LYL845; Shares Up 8%

October 6, 2022 | finance.yahoo.com

Lyell Immunopharma Announces FDA Clearance of its IND for LYL845, a TIL Product Candidate Enhanced with its Novel Epigenetic Reprogramming Technology for Solid Tumors

October 5, 2022 | finance.yahoo.com

Lyell Immunopharma to Present Preclinical Data Highlighting New T-Cell Reprogramming Technologies and its Growing Pipeline at 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting

September 28, 2022 | finance.yahoo.com

Lyell Immunopharma Announces the Appointment of Rahsaan Thompson as Chief Legal Officer

September 24, 2022 | seekingalpha.com

LYEL Lyell Immunopharma, Inc.

September 12, 2022 | finance.yahoo.com

Wall Street Analysts Believe Lyell Immunopharma (LYEL) Could Rally 91%: Here's is How to Trade

September 12, 2022 | markets.businessinsider.com

Lyell Immunopharma Climbs 13% In Morning Trade

September 12, 2022 | finance.yahoo.com

Lyell Immunopharma Presents First in Human Trial Design of LYL797 at ESMO 2022

August 26, 2022 | finance.yahoo.com

Wall Street Analysts Believe Lyell Immunopharma (LYEL) Could Rally 90%: Here's is How to Trade

August 10, 2022 | finance.yahoo.com

Can Lyell Immunopharma (LYEL) Climb 93% to Reach the Level Wall Street Analysts Expect?

August 8, 2022 | finance.yahoo.com

Growth Investors: Industry Analysts Just Upgraded Their Lyell Immunopharma, Inc. (NASDAQ:LYEL) Revenue Forecasts By 44%

August 7, 2022 | seekingalpha.com

Lyell Immunopharma (LYEL) Investor Presentation - Slideshow

August 4, 2022 | finance.yahoo.com

Lyell Immunopharma (LYEL) Reports Q2 Loss, Tops Revenue Estimates

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive LYEL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lyell Immunopharma and its competitors with MarketBeat's FREE daily newsletter.

LYEL Company Calendar

Last Earnings: 11/08/2022
Today: 12/08/2022
Fiscal Year End: 12/31/2022
Next Earnings (Estimated): 4/04/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:LYEL
CUSIP: N/A
CIK: 1806952
Web: www.lyell.com
Phone: 650-695-0677
Fax: N/A
Employees: 219
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $8.33
High Stock Price Forecast: $11.00
Low Stock Price Forecast: $7.00
Forecasted Upside/Downside: +116.5%
Consensus Rating: Hold
Rating Score (0-4): 2.33
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.89)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-250,220,000.00
Net Margins: -660.62%
Pretax Margin: -660.62%
Return on Equity: -29.54%
Return on Assets: -24.62%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 12.88
Quick Ratio: 12.88

Sales & Book Value

Annual Sales: $10.65 million
Price / Sales: 90.13
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.88 per share
Price / Book: 0.99

Miscellaneous

Outstanding Shares: 249,326,000
Free Float: 185,000,000
Market Cap: $959.91 million
Optionable: Not Optionable
Beta: -2.13

Key Executives

Dr. Richard D. Klausner M.D. (Age 70)
Founder & Exec. Chairman
Comp: $510.17k

Ms. Elizabeth Homans (Age 56)
CEO & Director
Comp: $988.85k

Mr. Charles W. Newton (Age 51)
Chief Financial Officer
Comp: $1.75M

Mr. Stephen J. Hill (Age 52)
Chief Operating Officer
Comp: $808.12k

Prof. Stanley R. Riddell M.D.
Founder & Scientific Advisor

Dr. Crystal L. Mackall M.D.
Founder & Scientific Advisor

Nellie Dillery
Director of Accounting

Mr. Richard Goold Ph.D. (Age 62)
Chief Information Officer

Dr. Gary Lee Ph.D. (Age 45)
Chief Scientific Officer

Ellen Rose
VP of Communications & Investor Relations

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

LYEL Stock - Frequently Asked Questions

Should I buy or sell Lyell Immunopharma stock right now?: 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Lyell Immunopharma in the last twelve months. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" LYEL shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in LYEL, but not buy additional shares or sell existing shares.
View LYEL analyst ratings or view top-rated stocks.
What is Lyell Immunopharma's stock price forecast for 2023?: 3 brokers have issued 1 year price targets for Lyell Immunopharma's shares. Their LYEL share price forecasts range from $7.00 to $11.00. On average, they expect the company's share price to reach $8.33 in the next year. This suggests a possible upside of 116.5% from the stock's current price.
View analysts price targets for LYEL or view top-rated stocks among Wall Street analysts.
How have LYEL shares performed in 2022?: Lyell Immunopharma's stock was trading at $7.74 at the start of the year. Since then, LYEL stock has decreased by 50.3% and is now trading at $3.85.
View the best growth stocks for 2022 here.
When is Lyell Immunopharma's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, April 4th 2023.
View our LYEL earnings forecast.
How were Lyell Immunopharma's earnings last quarter?: Lyell Immunopharma, Inc. (NASDAQ:LYEL) announced its quarterly earnings results on Tuesday, November, 8th. The company reported ($0.28) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.34) by $0.06. Lyell Immunopharma had a negative trailing twelve-month return on equity of 29.54% and a negative net margin of 660.62%.
When did Lyell Immunopharma IPO?: (LYEL) raised $425 million in an IPO on Thursday, June 17th 2021. The company issued 25,000,000 shares at $16.00-$18.00 per share. Goldman Sachs, BofA Securities, J.P. Morgan and Morgan Stanley acted as the underwriters for the IPO.

What is Lyell Immunopharma's stock symbol?: Lyell Immunopharma trades on the NASDAQ under the ticker symbol "LYEL."
Who are Lyell Immunopharma's major shareholders?: Lyell Immunopharma's stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (4.98%), BlackRock Inc. (4.70%), Foresite Capital Management IV LLC (4.01%), Alphabet Inc. (2.35%), State Street Corp (2.16%) and Price T Rowe Associates Inc. MD (2.13%). Insiders that own company stock include Cathy Friedman and Richard Klausner.
View institutional ownership trends.
How do I buy shares of Lyell Immunopharma?: Shares of LYEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Lyell Immunopharma's stock price today?: One share of LYEL stock can currently be purchased for approximately $3.85.
How much money does Lyell Immunopharma make?: Lyell Immunopharma (NASDAQ:LYEL) has a market capitalization of $959.91 million and generates $10.65 million in revenue each year. The company earns $-250,220,000.00 in net income (profit) each year or ($0.89) on an earnings per share basis.
How many employees does Lyell Immunopharma have?: The company employs 219 workers across the globe.
How can I contact Lyell Immunopharma?: The official website for the company is www.lyell.com. The company can be reached via phone at 650-695-0677 or via email at erose@lyell.com.

This page (NASDAQ:LYEL) was last updated on 12/8/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial